These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10224860)

  • 1. Lead toxicokinetics. Development of a biokinetic model to understand and predict the outcome of treatment.
    de Vries I; Spaans E; van Dijk A; Meulenbelt J
    Przegl Lek; 1998; 55(10):500-4. PubMed ID: 10224860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New directions in the toxicokinetics of human lead exposure.
    Mushak P
    Neurotoxicology; 1993; 14(2-3):29-42. PubMed ID: 8247403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases.
    Lin-Tan DT; Lin JL; Yen TH; Chen KH; Huang YL
    Nephrol Dial Transplant; 2007 Oct; 22(10):2924-31. PubMed ID: 17556414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and modification of a physiologically based model of lead kinetics using data from a sequential isotope study in cynomolgus monkeys.
    O'Flaherty EJ; Inskip MJ; Franklin CA; Durbin PW; Manton WI; Baccanale CL
    Toxicol Appl Pharmacol; 1998 Mar; 149(1):1-16. PubMed ID: 9512721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure.
    Cremin JD; Luck ML; Laughlin NK; Smith DR
    Toxicol Appl Pharmacol; 1999 Dec; 161(3):283-93. PubMed ID: 10620486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of chelation therapy with succimer in young rabbits of moderate lead poisoning].
    Yu GY; Yan CH; Yu XG; Zuo Y; Zou XY; Xu J; Wu SH; Shen XM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jan; 43(1):8-13. PubMed ID: 19534872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level environmental exposure to lead and progressive chronic kidney diseases.
    Lin JL; Lin-Tan DT; Li YJ; Chen KH; Huang YL
    Am J Med; 2006 Aug; 119(8):707.e1-9. PubMed ID: 16887418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The study of age influence on human bone lead metabolism by using a simplified model and X-ray fluorescence data.
    Nie H; Chettle DR; Webber CE; Brito JA; O'Meara JM; McNeill FE
    J Environ Monit; 2005 Nov; 7(11):1069-73. PubMed ID: 16252055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic model to describe the disposition of lead in the rat.
    Bornemann LD; Colburn WA
    J Toxicol Environ Health; 1985; 16(3-4):631-9. PubMed ID: 4087323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The O'Flaherty model of lead kinetics: an evaluation using data from a lead smelter population.
    Fleming DE; Chettle DR; Webber CE; O'Flaherty EJ
    Toxicol Appl Pharmacol; 1999 Nov; 161(1):100-9. PubMed ID: 10558927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of bone-lead stores on the observed effectiveness of lead hazard intervention.
    Rust SW; Kumar P; Burgoon DA; Niemuth NA; Schultz BD
    Environ Res; 1999 Oct; 81(3):175-84. PubMed ID: 10585013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead toxicity, a review of the literature. Part 1: Exposure, evaluation, and treatment.
    Patrick L
    Altern Med Rev; 2006 Mar; 11(1):2-22. PubMed ID: 16597190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead risk assessment for children in Hungary by predicting their blood lead levels using US EPA integrated Exposure Uptake Biokinetic model.
    Hassanien MA; Horváth A
    Cent Eur J Public Health; 1999 Aug; 7(3):155-9. PubMed ID: 10499150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead poisoning--Part I. Incidence, etiology, and toxicokinetics.
    Philip AT; Gerson B
    Clin Lab Med; 1994 Jun; 14(2):423-44. PubMed ID: 7924196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histopathology of tissue lead retention.
    Greenberg SR
    Histol Histopathol; 1990 Oct; 5(4):451-6. PubMed ID: 2134397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Aug; 443():1-321. PubMed ID: 12595920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified natural clinoptilolite detoxifies small mammal's organism loaded with lead I. Lead disposition and kinetic model for lead bioaccumulation.
    Beltcheva M; Metcheva R; Popov N; Teodorova SE; Heredia-Rojas JA; Rodríguez-de la Fuente AO; Rodríguez-Flores LE; Topashka-Ancheva M
    Biol Trace Elem Res; 2012 Jun; 147(1-3):180-8. PubMed ID: 22147334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined exchange transfusion and chelation therapy for neonatal lead poisoning.
    Mycyk MB; Leikin JB
    Ann Pharmacother; 2004 May; 38(5):821-4. PubMed ID: 15026564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.